https://www.ncbi.nlm.nih.gov/pubmed/29079315 \ Nutrition associated liver disease

J Pediatr Surg. 2017 Oct 12. pii: S0022-3468(17)30652-8. doi: 10.1016/j.jpedsurg.2017.10.030. [Epub ahead of print]

Gonzalez-Hernandez J, Prajapati P, Ogola G, Nguyen V, Channabasappa N, Piper HG.

Abstract

PURPOSE:

The purpose of this study was to compare outcomes of lipid minimization with either Intralipid (IL) or Omegaven® in children with intestinal failure (IF) who developed intestinal failure-associated liver disease (IFALD) while receiving parenteral nutrition (PN).

METHODS:

A retrospective review of children with IF requiring PN who developed IFALD (direct bilirubin >2 mg/dL) while receiving IL (2009-2016) was performed. Clinical characteristics, nutritional, and laboratory values were compared between children treated with reduced IL or Omegaven®.

RESULTS:

16 children were reviewed (8 treated with IL and 8 treated with Omegaven® at a median dose of 1g/kg/d). Both groups had similar demographics, small bowel length, and parenteral nutritional intake during the study (82.9±27.1 kcal/kg/d vs. 75.9±16.5 kcal/kg/d, p=0.54). The mean direct bilirubin (DBili) prior to initiating treatment was 7.8±4.3 mg/dL and 7.5±3.5 mg/dL (p=0.87) in the IL and Omegaven® groups, respectively. The IL group took a median of 113 days to achieve a DBili <0.5 mg/dL compared to 124 days in the Omegaven® group (p=0.49). There were no differences in markers of liver function or growth trajectories among groups.

CONCLUSIONS:

Lipid minimization with either IL or Omegaven® has similar success in achieving a normal DBili in children with IF and IFALD without major differences in nutritional status or growth.

TYPE OF STUDY:

Treatment Study LEVEL OF EVIDENCE: III.